# Defining the Role of Viral Infections and Autoantibodies in Chronic Obstructive Pulmonary Disease Progression

> **NIH NIH R01** · JOHNS HOPKINS UNIVERSITY · 2024 · $675,739

## Abstract

PROJECT SUMMARY
Multiple lines of evidence point to the role of adaptive immunity as response to viral infections and/or as
misdirected autoimmune response in subjects with COPD and emphysema. There is support for an association
between adaptive immune responses and COPD progression, but a direct link has not been made. In this
proposal, we will utilize blood samples from 3,000 well-characterized subjects from the COPDGene Study, which
include longitudinal follow-up and extensive available omics datasets. We will employ state of the art Phage
ImmunoPrecipitation Sequencing (PhIP-Seq) technology to efficiently and comprehensively assess samples for
autoantibodies and antibodies indicative of prior viral infections. Our first hypothesis is that previous infections with
respiratory viruses, or differential immune responses to viral infections, are associated with more rapid
progression of COPD, speciﬁcally lung function decline. The second hypothesis is that autoantibodies are
associated with COPD, emphysema, and more rapid lung function decline. Aim 1: Human Virome and Lung
Function Decline. We will test for associations between baseline viral antibodies and longitudinal decline in lung
function at the 5 and 10-year study visits. We will also measure antiviral antibodies at the 5-year visit and test for
lung function decline over the subsequent 5 years in subjects who acquire new or higher levels of specific viral
antibodies, signifying interval infections. We will test whether these effects are modified by host factors including
sex and HLA genotypes. Aim 2: Autoimmunity and COPD Outcomes. We will use PhIP-Seq to identify the
presence of autoantibodies, we and will test for association between autoantibodies and COPD status, lung
function decline, and quantitative emphysema parameters from chest CT scans. We will measure autoantibodies
at the 5-year visit and test for lung function decline over the subsequent 5 years in subjects who acquire new or
higher levels of autoantibodies. We will again test whether these effects are modified by host factors including sex
and HLA genotypes. Aim 3: Adaptive Immunity and Chronic Inflammation Using whole blood RNA-
sequencing data from the year 5 visit, we will derive gene expression scores representing antiviral and
inﬂammatory pathways. We will test the association of these gene expression scores with viral antibodies and
autoantibodies to discover novel drivers of persistent inﬂammation. We will validate the association of
inﬂammatory gene expression scores with lung function and CT emphysema in a larger sample of COPDGene
subjects with RNA-sequencing data. This proposal will complement the existing clinical, genetic and
transcriptomic data in COPDGene by incorporating viral exposures and autoantibodies into longitudinal models
of COPD progression. To accomplish this research, we have assembled a multidisciplinary team with expertise
in in PhIP-Seq, COPD phenotyping, molecular immunology, genetic epidemiolo...

## Key facts

- **NIH application ID:** 10803040
- **Project number:** 1R01HL168663-01A1
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** CRAIG P HERSH
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $675,739
- **Award type:** 1
- **Project period:** 2024-07-16 → 2028-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10803040

## Citation

> US National Institutes of Health, RePORTER application 10803040, Defining the Role of Viral Infections and Autoantibodies in Chronic Obstructive Pulmonary Disease Progression (1R01HL168663-01A1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10803040. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
